Global Peptide Cancer Vaccine Market Insights and Forecast to 2028

Report ID: 1154175 | Published Date: Jan 2025 | No. of Page: 108 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Peptide Cancer Vaccine Product Introduction
    1.2 Market by Pipeline
        1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline, 2017 VS 2021 VS 2028
        1.2.2 ITK-1
        1.2.3 GRN-1201
        1.2.4 TPIV200
        1.2.5 TPIV110
        1.2.6 UV1
        1.2.7 Galinpepimut-S
        1.2.8 TARP 27-35
        1.2.9 HER-Vaxx
        1.2.10 Vx-001
        1.2.11 Others
    1.3 Market by Application
        1.3.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Breast Cancer
        1.3.3 Lung Cancer
        1.3.4 Melanoma
        1.3.5 Prostate Cancer
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2017-2028
    2.2 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts 2017-2028
    2.3 Global Peptide Cancer Vaccine Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Peptide Cancer Vaccine Sales by Region
        2.4.1 Global Peptide Cancer Vaccine Sales by Region (2017-2022)
        2.4.2 Global Sales Peptide Cancer Vaccine by Region (2023-2028)
    2.5 Global Peptide Cancer Vaccine Revenue by Region
        2.5.1 Global Peptide Cancer Vaccine Revenue by Region (2017-2022)
        2.5.2 Global Peptide Cancer Vaccine Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Peptide Cancer Vaccine Sales by Manufacturers
        3.1.1 Global Top Peptide Cancer Vaccine Manufacturers by Sales (2017-2022)
        3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Peptide Cancer Vaccine in 2021
    3.2 Global Peptide Cancer Vaccine Revenue by Manufacturers
        3.2.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2017-2022)
        3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2021
    3.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Peptide Cancer Vaccine Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Pipeline
    4.1 Global Peptide Cancer Vaccine Sales by Pipeline
        4.1.1 Global Peptide Cancer Vaccine Historical Sales by Pipeline (2017-2022)
        4.1.2 Global Peptide Cancer Vaccine Forecasted Sales by Pipeline (2023-2028)
        4.1.3 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    4.2 Global Peptide Cancer Vaccine Revenue by Pipeline
        4.2.1 Global Peptide Cancer Vaccine Historical Revenue by Pipeline (2017-2022)
        4.2.2 Global Peptide Cancer Vaccine Forecasted Revenue by Pipeline (2023-2028)
        4.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    4.3 Global Peptide Cancer Vaccine Price by Pipeline
        4.3.1 Global Peptide Cancer Vaccine Price by Pipeline (2017-2022)
        4.3.2 Global Peptide Cancer Vaccine Price Forecast by Pipeline (2023-2028)
5 Market Size by Application
    5.1 Global Peptide Cancer Vaccine Sales by Application
        5.1.1 Global Peptide Cancer Vaccine Historical Sales by Application (2017-2022)
        5.1.2 Global Peptide Cancer Vaccine Forecasted Sales by Application (2023-2028)
        5.1.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    5.2 Global Peptide Cancer Vaccine Revenue by Application
        5.2.1 Global Peptide Cancer Vaccine Historical Revenue by Application (2017-2022)
        5.2.2 Global Peptide Cancer Vaccine Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    5.3 Global Peptide Cancer Vaccine Price by Application
        5.3.1 Global Peptide Cancer Vaccine Price by Application (2017-2022)
        5.3.2 Global Peptide Cancer Vaccine Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Peptide Cancer Vaccine Market Size by Pipeline
        6.1.1 North America Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
        6.1.2 North America Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
    6.2 North America Peptide Cancer Vaccine Market Size by Application
        6.2.1 North America Peptide Cancer Vaccine Sales by Application (2017-2028)
        6.2.2 North America Peptide Cancer Vaccine Revenue by Application (2017-2028)
    6.3 North America Peptide Cancer Vaccine Market Size by Country
        6.3.1 North America Peptide Cancer Vaccine Sales by Country (2017-2028)
        6.3.2 North America Peptide Cancer Vaccine Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
        7.1.1 Europe Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
        7.1.2 Europe Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
    7.2 Europe Peptide Cancer Vaccine Market Size by Application
        7.2.1 Europe Peptide Cancer Vaccine Sales by Application (2017-2028)
        7.2.2 Europe Peptide Cancer Vaccine Revenue by Application (2017-2028)
    7.3 Europe Peptide Cancer Vaccine Market Size by Country
        7.3.1 Europe Peptide Cancer Vaccine Sales by Country (2017-2028)
        7.3.2 Europe Peptide Cancer Vaccine Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Peptide Cancer Vaccine Market Size by Pipeline
        8.1.1 Asia Pacific Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
        8.1.2 Asia Pacific Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
    8.2 Asia Pacific Peptide Cancer Vaccine Market Size by Application
        8.2.1 Asia Pacific Peptide Cancer Vaccine Sales by Application (2017-2028)
        8.2.2 Asia Pacific Peptide Cancer Vaccine Revenue by Application (2017-2028)
    8.3 Asia Pacific Peptide Cancer Vaccine Market Size by Region
        8.3.1 Asia Pacific Peptide Cancer Vaccine Sales by Region (2017-2028)
        8.3.2 Asia Pacific Peptide Cancer Vaccine Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Peptide Cancer Vaccine Market Size by Pipeline
        9.1.1 Latin America Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
        9.1.2 Latin America Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
    9.2 Latin America Peptide Cancer Vaccine Market Size by Application
        9.2.1 Latin America Peptide Cancer Vaccine Sales by Application (2017-2028)
        9.2.2 Latin America Peptide Cancer Vaccine Revenue by Application (2017-2028)
    9.3 Latin America Peptide Cancer Vaccine Market Size by Country
        9.3.1 Latin America Peptide Cancer Vaccine Sales by Country (2017-2028)
        9.3.2 Latin America Peptide Cancer Vaccine Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Peptide Cancer Vaccine Market Size by Pipeline
        10.1.1 Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
        10.1.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
    10.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Application
        10.2.1 Middle East and Africa Peptide Cancer Vaccine Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2017-2028)
    10.3 Middle East and Africa Peptide Cancer Vaccine Market Size by Country
        10.3.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Boston Biomedical
        11.1.1 Boston Biomedical Corporation Information
        11.1.2 Boston Biomedical Overview
        11.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Boston Biomedical Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Boston Biomedical Recent Developments
    11.2 Ultimovacs
        11.2.1 Ultimovacs Corporation Information
        11.2.2 Ultimovacs Overview
        11.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Ultimovacs Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Ultimovacs Recent Developments
    11.3 BrightPath Biotherapeutics
        11.3.1 BrightPath Biotherapeutics Corporation Information
        11.3.2 BrightPath Biotherapeutics Overview
        11.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 BrightPath Biotherapeutics Recent Developments
    11.4 TapImmune
        11.4.1 TapImmune Corporation Information
        11.4.2 TapImmune Overview
        11.4.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 TapImmune Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 TapImmune Recent Developments
    11.5 Immatics
        11.5.1 Immatics Corporation Information
        11.5.2 Immatics Overview
        11.5.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Immatics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Immatics Recent Developments
    11.6 Sellas
        11.6.1 Sellas Corporation Information
        11.6.2 Sellas Overview
        11.6.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Sellas Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Sellas Recent Developments
    11.7 Imugene
        11.7.1 Imugene Corporation Information
        11.7.2 Imugene Overview
        11.7.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Imugene Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Imugene Recent Developments
    11.8 VAXON Biotech
        11.8.1 VAXON Biotech Corporation Information
        11.8.2 VAXON Biotech Overview
        11.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 VAXON Biotech Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 VAXON Biotech Recent Developments
    11.9 Generex Biotechnology
        11.9.1 Generex Biotechnology Corporation Information
        11.9.2 Generex Biotechnology Overview
        11.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Generex Biotechnology Recent Developments
    11.10 ISA Pharmaceuticals
        11.10.1 ISA Pharmaceuticals Corporation Information
        11.10.2 ISA Pharmaceuticals Overview
        11.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 ISA Pharmaceuticals Recent Developments
    11.11 OncoTherapy Science
        11.11.1 OncoTherapy Science Corporation Information
        11.11.2 OncoTherapy Science Overview
        11.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 OncoTherapy Science Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Peptide Cancer Vaccine Industry Chain Analysis
    12.2 Peptide Cancer Vaccine Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Peptide Cancer Vaccine Production Mode & Process
    12.4 Peptide Cancer Vaccine Sales and Marketing
        12.4.1 Peptide Cancer Vaccine Sales Channels
        12.4.2 Peptide Cancer Vaccine Distributors
    12.5 Peptide Cancer Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Peptide Cancer Vaccine Industry Trends
    13.2 Peptide Cancer Vaccine Market Drivers
    13.3 Peptide Cancer Vaccine Market Challenges
    13.4 Peptide Cancer Vaccine Market Restraints
14 Key Findings in The Global Peptide Cancer Vaccine Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of ITK-1
    Table 3. Major Manufacturers of GRN-1201
    Table 4. Major Manufacturers of TPIV200
    Table 5. Major Manufacturers of TPIV110
    Table 6. Major Manufacturers of UV1
    Table 7. Major Manufacturers of Galinpepimut-S
    Table 8. Major Manufacturers of TARP 27-35
    Table 9. Major Manufacturers of HER-Vaxx
    Table 10. Major Manufacturers of Vx-001
    Table 11. Major Manufacturers of Others
    Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 13. Global Peptide Cancer Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 14. Global Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
    Table 15. Global Peptide Cancer Vaccine Sales Market Share by Region (2017-2022)
    Table 16. Global Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
    Table 17. Global Peptide Cancer Vaccine Sales Market Share by Region (2023-2028)
    Table 18. Global Peptide Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 19. Global Peptide Cancer Vaccine Revenue Market Share by Region (2017-2022)
    Table 20. Global Peptide Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 21. Global Peptide Cancer Vaccine Revenue Market Share by Region (2023-2028)
    Table 22. Global Peptide Cancer Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
    Table 23. Global Peptide Cancer Vaccine Sales Share by Manufacturers (2017-2022)
    Table 24. Global Peptide Cancer Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 25. Global Peptide Cancer Vaccine Revenue Share by Manufacturers (2017-2022)
    Table 26. Peptide Cancer Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
    Table 27. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 28. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2021)
    Table 29. Peptide Cancer Vaccine Manufacturing Base Distribution and Headquarters
    Table 30. Manufacturers Peptide Cancer Vaccine Product Offered
    Table 31. Date of Manufacturers Enter into Peptide Cancer Vaccine Market
    Table 32. Mergers & Acquisitions, Expansion Plans
    Table 33. Global Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
    Table 34. Global Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
    Table 35. Global Peptide Cancer Vaccine Sales Share by Pipeline (2017-2022)
    Table 36. Global Peptide Cancer Vaccine Sales Share by Pipeline (2023-2028)
    Table 37. Global Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
    Table 38. Global Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
    Table 39. Global Peptide Cancer Vaccine Revenue Share by Pipeline (2017-2022)
    Table 40. Global Peptide Cancer Vaccine Revenue Share by Pipeline (2023-2028)
    Table 41. Peptide Cancer Vaccine Price by Pipeline (2017-2022) & (USD/Dose)
    Table 42. Global Peptide Cancer Vaccine Price Forecast by Pipeline (2023-2028) & (USD/Dose)
    Table 43. Global Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 44. Global Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 45. Global Peptide Cancer Vaccine Sales Share by Application (2017-2022)
    Table 46. Global Peptide Cancer Vaccine Sales Share by Application (2023-2028)
    Table 47. Global Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 48. Global Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 49. Global Peptide Cancer Vaccine Revenue Share by Application (2017-2022)
    Table 50. Global Peptide Cancer Vaccine Revenue Share by Application (2023-2028)
    Table 51. Peptide Cancer Vaccine Price by Application (2017-2022) & (USD/Dose)
    Table 52. Global Peptide Cancer Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
    Table 53. North America Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
    Table 54. North America Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
    Table 55. North America Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
    Table 56. North America Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
    Table 57. North America Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 58. North America Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 59. North America Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 60. North America Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 61. North America Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 62. North America Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 63. North America Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 64. North America Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 65. Europe Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
    Table 66. Europe Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
    Table 67. Europe Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
    Table 68. Europe Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
    Table 69. Europe Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 70. Europe Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 71. Europe Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 72. Europe Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 73. Europe Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 74. Europe Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 75. Europe Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 76. Europe Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
    Table 78. Asia Pacific Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
    Table 79. Asia Pacific Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
    Table 81. Asia Pacific Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 82. Asia Pacific Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 83. Asia Pacific Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 84. Asia Pacific Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 85. Asia Pacific Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
    Table 86. Asia Pacific Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
    Table 87. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
    Table 88. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
    Table 89. Latin America Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
    Table 90. Latin America Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
    Table 91. Latin America Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
    Table 92. Latin America Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
    Table 93. Latin America Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 94. Latin America Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 95. Latin America Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 96. Latin America Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 97. Latin America Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 98. Latin America Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 99. Latin America Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 100. Latin America Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
    Table 102. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
    Table 103. Middle East and Africa Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
    Table 105. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
    Table 106. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
    Table 107. Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
    Table 108. Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
    Table 109. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
    Table 110. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
    Table 111. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
    Table 112. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
    Table 113. Boston Biomedical Corporation Information
    Table 114. Boston Biomedical Description and Major Businesses
    Table 115. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 116. Boston Biomedical Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. Boston Biomedical Recent Developments
    Table 118. Ultimovacs Corporation Information
    Table 119. Ultimovacs Description and Major Businesses
    Table 120. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 121. Ultimovacs Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Ultimovacs Recent Developments
    Table 123. BrightPath Biotherapeutics Corporation Information
    Table 124. BrightPath Biotherapeutics Description and Major Businesses
    Table 125. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 126. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. BrightPath Biotherapeutics Recent Developments
    Table 128. TapImmune Corporation Information
    Table 129. TapImmune Description and Major Businesses
    Table 130. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 131. TapImmune Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. TapImmune Recent Developments
    Table 133. Immatics Corporation Information
    Table 134. Immatics Description and Major Businesses
    Table 135. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 136. Immatics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. Immatics Recent Developments
    Table 138. Sellas Corporation Information
    Table 139. Sellas Description and Major Businesses
    Table 140. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 141. Sellas Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. Sellas Recent Developments
    Table 143. Imugene Corporation Information
    Table 144. Imugene Description and Major Businesses
    Table 145. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 146. Imugene Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. Imugene Recent Developments
    Table 148. VAXON Biotech Corporation Information
    Table 149. VAXON Biotech Description and Major Businesses
    Table 150. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 151. VAXON Biotech Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 152. VAXON Biotech Recent Developments
    Table 153. Generex Biotechnology Corporation Information
    Table 154. Generex Biotechnology Description and Major Businesses
    Table 155. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 156. Generex Biotechnology Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 157. Generex Biotechnology Recent Developments
    Table 158. ISA Pharmaceuticals Corporation Information
    Table 159. ISA Pharmaceuticals Description and Major Businesses
    Table 160. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 161. ISA Pharmaceuticals Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 162. ISA Pharmaceuticals Recent Developments
    Table 163. OncoTherapy Science Corporation Information
    Table 164. OncoTherapy Science Description and Major Businesses
    Table 165. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
    Table 166. OncoTherapy Science Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
    Table 167. OncoTherapy Science Recent Developments
    Table 168. Key Raw Materials Lists
    Table 169. Raw Materials Key Suppliers Lists
    Table 170. Peptide Cancer Vaccine Distributors List
    Table 171. Peptide Cancer Vaccine Customers List
    Table 172. Peptide Cancer Vaccine Market Trends
    Table 173. Peptide Cancer Vaccine Market Drivers
    Table 174. Peptide Cancer Vaccine Market Challenges
    Table 175. Peptide Cancer Vaccine Market Restraints
    Table 176. Research Programs/Design for This Report
    Table 177. Key Data Information from Secondary Sources
    Table 178. Key Data Information from Primary Sources
List of Figures
    Figure 1. Peptide Cancer Vaccine Product Picture
    Figure 3. Global Peptide Cancer Vaccine Market Share by Pipeline in 2021 & 2028
    Figure 3. ITK-1 Product Picture
    Figure 4. GRN-1201 Product Picture
    Figure 5. TPIV200 Product Picture
    Figure 6. TPIV110 Product Picture
    Figure 7. UV1 Product Picture
    Figure 8. Galinpepimut-S Product Picture
    Figure 9. TARP 27-35 Product Picture
    Figure 10. HER-Vaxx Product Picture
    Figure 11. Vx-001 Product Picture
    Figure 12. Others Product Picture
    Figure 13. Global Peptide Cancer Vaccine Market Share by Application in 2021 & 2028
    Figure 14. Breast Cancer
    Figure 15. Lung Cancer
    Figure 16. Melanoma
    Figure 17. Prostate Cancer
    Figure 18. Others
    Figure 19. Peptide Cancer Vaccine Report Years Considered
    Figure 20. Global Peptide Cancer Vaccine Sales 2017-2028 (K Doses)
    Figure 21. Global Peptide Cancer Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 22. Global Peptide Cancer Vaccine Revenue 2017-2028 (US$ Million)
    Figure 23. Global Peptide Cancer Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 24. Global Peptide Cancer Vaccine Sales Market Share by Region (2017-2022)
    Figure 25. Global Peptide Cancer Vaccine Sales Market Share by Region (2023-2028)
    Figure 26. North America Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 27. North America Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Europe Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 29. Europe Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 31. Asia-Pacific Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 32. Latin America Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 33. Latin America Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 34. Middle East & Africa Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
    Figure 35. Middle East & Africa Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
    Figure 36. The Peptide Cancer Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 37. The Top 5 and 10 Largest Manufacturers of Peptide Cancer Vaccine in the World: Market Share by Peptide Cancer Vaccine Revenue in 2021
    Figure 38. Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 39. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    Figure 40. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    Figure 41. Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    Figure 42. Global Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    Figure 43. North America Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    Figure 44. North America Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    Figure 45. North America Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    Figure 46. North America Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    Figure 47. North America Peptide Cancer Vaccine Sales Share by Country (2017-2028)
    Figure 48. North America Peptide Cancer Vaccine Revenue Share by Country (2017-2028)
    Figure 49. U.S. Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 50. Canada Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 51. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    Figure 52. Europe Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    Figure 53. Europe Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    Figure 54. Europe Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    Figure 55. Europe Peptide Cancer Vaccine Sales Share by Country (2017-2028)
    Figure 56. Europe Peptide Cancer Vaccine Revenue Share by Country (2017-2028)
    Figure 57. Germany Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 58. France Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 59. U.K. Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 60. Italy Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 61. Russia Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 62. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    Figure 63. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    Figure 64. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    Figure 65. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    Figure 66. Asia Pacific Peptide Cancer Vaccine Sales Share by Region (2017-2028)
    Figure 67. Asia Pacific Peptide Cancer Vaccine Revenue Share by Region (2017-2028)
    Figure 68. China Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 69. Japan Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 70. South Korea Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 71. India Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 72. Australia Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 73. Taiwan Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 74. Indonesia Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 75. Thailand Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 76. Malaysia Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 77. Philippines Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 78. Latin America Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    Figure 79. Latin America Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    Figure 80. Latin America Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    Figure 81. Latin America Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    Figure 82. Latin America Peptide Cancer Vaccine Sales Share by Country (2017-2028)
    Figure 83. Latin America Peptide Cancer Vaccine Revenue Share by Country (2017-2028)
    Figure 84. Mexico Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 85. Brazil Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 86. Argentina Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 87. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
    Figure 88. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
    Figure 89. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
    Figure 90. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
    Figure 91. Middle East and Africa Peptide Cancer Vaccine Sales Share by Country (2017-2028)
    Figure 92. Middle East and Africa Peptide Cancer Vaccine Revenue Share by Country (2017-2028)
    Figure 93. Turkey Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 94. Saudi Arabia Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 95. U.A.E Peptide Cancer Vaccine Revenue (2017-2028) & (US$ Million)
    Figure 96. Peptide Cancer Vaccine Value Chain
    Figure 97. Peptide Cancer Vaccine Production Process
    Figure 98. Channels of Distribution
    Figure 99. Distributors Profiles
    Figure 100. Bottom-up and Top-down Approaches for This Report
    Figure 101. Data Triangulation
    Figure 102. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Frequently Asked Questions
Peptide Cancer Vaccine report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Peptide Cancer Vaccine report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Peptide Cancer Vaccine report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Coffee Makers

Coffee Makers market is segmented by Type and by Application. Players, stakeholders, and other pa ... Read More

Firestop Sealants

Firestop Sealants market is segmented by Type and by Application. Players, stakeholders, and othe ... Read More